Stay updated on Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    Expanded the study Locations to include numerous sites across the US, Canada, Europe, and Australia, with many regional entries added and others removed.
    Difference
    4%
    Check dated 2025-12-21T21:33:23.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    28 days ago
    Change Detected
    Summary
    The only visible change is the page footer showing Revision: v3.3.2 instead of v3.3.1 on the ClinicalTrials.gov page. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2025-11-30T07:29:49.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    Publications section wording was updated to indicate PubMed-sourced publications may not be about the study, and the revision tag changed from v3.2.0 to v3.3.1.
    Difference
    0.2%
    Check dated 2025-11-23T08:12:41.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    The Locations entry was updated to replace 'Tainan City, Taiwan, 704' with 'Tainan, Taiwan, 704', and a government funding notice was removed from the page.
    Difference
    0.1%
    Check dated 2025-11-16T06:02:57.000Z thumbnail image
  7. Check
    49 days ago
    Change Detected
    Summary
    Updates include addition of date-like entries (2025-11-05, 2026-07, 2025-11-04, 2025-11) and deletions of older entries (2025-08-26, 2025-10, 2025-08-22, 2025-08), as well as handling of duplicate site records (Gabrail Cancer Center Research /ID# 216056; Duplicate_Shizuoka Cancer Center /ID# 205065) and CSR removal. These changes are limited to metadata and duplicate records and do not affect core study content such as eligibility criteria or primary outcomes.
    Difference
    0.1%
    Check dated 2025-11-09T03:25:26.000Z thumbnail image
  8. Check
    56 days ago
    Change Detected
    Summary
    The new screenshot shows minor UI adjustments and formatting changes on the study details page, while the core information (title, conditions, eligibility, enrollment, and locations) appears unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-02T00:14:49.000Z thumbnail image

Stay in the know with updates to Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial page.